IBO
AMEXImpact BioMedical Inc.
Impact BioMedical Inc. (IBO) is a Biotechnology: Pharmaceutical Preparations company listed on AMEX. In the last 30 days Quantisnow tracked 5 wire items for IBO, including 3 SEC filings and 2 market updates. The most recent was published Nov 3, 2026.
Financial highlights
Full financials- Revenue, TTM
- $35.0K
- Net income, TTM
- $789.0K
- Net margin
- 2254.3%
- Cash
- $10.0K
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks13-33%
2026-05-102026-11-01
Mix1290d
- SEC Filings5(42%)
- Other4(33%)
- Market2(17%)
- Insider1(8%)
Latest news
25 items- SECImpact BioMedical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- NEWSDSS, Inc. Announces SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business CombinationSpecial meeting of Impact Biomedical stockholders to approve the proposed Business Combination scheduled for November 13, 2026, at 10:00 a.m. Eastern Standard TimeUpon closing, the combined company is expected to operate as Zoar Limited and trade on NYSE American under the ticker symbol "ZOAR," subject to listing approval ROCHESTER, NY / ACCESS Newswire / November 2, 2026 / DSS, Inc. (NYSE:DSS) ("DSS"), majority shareholder of Impact Biomedical Inc. (NYSE:IBO) ("Impact"), and Zoar Limited (f/k/a Dr. Ashley's Limited) ("PubCo") announced that the U.S. Securities and Exchange Commission ("SEC") declared effective on October 23, 2026, PubCo's registration statement on Form F-4 (the "Regis
- NEWSImpact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business CombinationSpecial meeting of Impact Biomedical stockholders to approve the proposed Business Combination scheduled for November 13, 2026, at 10:00 a.m. Eastern Standard TimeUpon closing, the combined company is expected to operate as Zoar Limited and trade on NYSE American under the ticker symbol "ZOAR," subject to listing approval HOUSTON, TX / ACCESS Newswire / November 2, 2026 / Impact Biomedical Inc. (NYSE:IBO) ("Impact" or the "Company") and Zoar Limited (f/k/a Dr. Ashley's Limited) ("PubCo") announced that the U.S. Securities and Exchange Commission ("SEC") declared effective on October 23, 2026, PubCo's registration statement on Form F-4 (the "Registration Statement") in connection with t
- SECSEC Form DEFM14A filed by Impact BioMedical Inc.DEFM14A - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECSEC Form 8-K filed by Impact BioMedical Inc.8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- INSIDERLarge owner Dss, Inc. sold $1,686 worth of shares (906 units at $1.86), decreasing direct ownership by 0.15% to 589,518 units (SEC Form 4)4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
- PRDSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar LimitedROCHESTER, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE:DSS) ("DSS" or the "Company") today announced that Zoar Limited ("Zoar" or "PubCo") has filed a Registration Statement on Form F-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") in connection with the previously announced proposed business combination (the "Business Combination") involving Impact Biomedical Inc. (NYSE:IBO) ("Impact"), Zoar and certain related parties. DSS is a significant stockholder of Impact Biomedical, and the filing represents an important step in Impact’s proposed Business Combination with Zoar. "We are pleased to see Impact reach this important milestone in
- PRImpact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (NYSE:IBO) (the "Company" or "Impact") announced that a Form F-4 registration statement (the "Registration Statement") was filed with the U.S. Securities and Exchange Commission (the "SEC") on Thursday, September 10, 2026, by Zoar Limited ("PubCo") in connection with the previously announced business combination (the "Business Combination") with, among others, PubCo and Zoar Labs Limited (f/k/a Dr. Ashley’s Bio Labs Limited) ("Zoar Labs"), which includes Impact’s preliminary proxy statement. The F-4 Registration Statement is available through the SEC’s website at www.sec.gov under the name "Zoar Limited". The management of
- SECImpact BioMedical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- PRCORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the "Company" or "Impact") dated September 11, 2026. The original press release incorrectly stated that Impact stockholders would receive one (1) share of Zoar Limited for every four (4) shares of Impact Common Stock (defined below). The correct exchange ratio, as set forth in the Merger and Share Exchange Agreement as Exhibit 2.1 to the current report on Form 8-K dated June 23, 2025 (Accession No.0001641172-25-016002), is one (1) share of Zoar Limited for every one (1) share of Impact Commo
- PRImpact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.)HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (the "Company") today announced that the Company's Board of Directors has approved a 1 for 12.62 reverse stock split of the Company's issued and outstanding common stock, par value $0.001 per share (the "Common Stock"). The reverse stock split will become effective at 12:01 a.m., Eastern Time, on September 23, 2026. Starting with the opening of trading on that date, the Company’s Common Stock will continue to trade on the NYSE American Exchange under the ticker symbol "IBO" and will trade under a new CUSIP number to be assigned in connection with the reverse stock split. On December 30, 2025, the Company's stockholders a
- SECSEC Form 10-Q filed by Impact BioMedical Inc.10-Q - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECSEC Form 10-Q filed by Impact BioMedical Inc.10-Q - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECSEC Form 144 filed by Impact BioMedical Inc.144 - IMPACT BIOMEDICAL INC. (0001834105) (Subject)
- SECSEC Form S-8 POS filed by Impact BioMedical Inc.S-8 POS - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECSEC Form S-8 POS filed by Impact BioMedical Inc.S-8 POS - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- PRImpact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger PlansHOUSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO) announced that its annual report(10-K) for the fiscal year ending December 31, 2025, filed on March 11, 2026, includes an audit opinion from Grassi & Co., CPAs, P.C. that contains a "going concern" qualification. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph and does not represent any change or amendment to the Company's financial statements for the year ended December 31, 2025. Again, this announcement does not represent any change or amendment to the Company's finan
- INSIDERSEC Form 4 filed by Macko Todd D4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
- INSIDERSEC Form 4 filed by Grady Jason4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
- SECSEC Form 10-K filed by Impact BioMedical Inc.10-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECImpact BioMedical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- INSIDERLarge owner Dss, Inc. sold $88,006 worth of shares (161,000 units at $0.55), decreasing direct ownership by 23% to 545,024 units (SEC Form 4)4 - IMPACT BIOMEDICAL INC. (0001834105) (Issuer)
- SECSEC Form DEF 14C filed by Impact BioMedical Inc.DEF 14C - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECSEC Form PRE 14C filed by Impact BioMedical Inc.PRE 14C - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
- SECSEC Form 10-Q filed by Impact BioMedical Inc.10-Q - IMPACT BIOMEDICAL INC. (0001834105) (Filer)
IBO FAQ
9 questionsWhat is the latest news on IBO?
In the last 30 days Quantisnow tracked 5 wire items for IBO: 3 SEC filings and 2 market updates. The most recent was published on November 3, 2026.What is IBO revenue?
Impact BioMedical Inc. (IBO) reported $35.0K of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $32.0K.Is IBO profitable?
Yes. Impact BioMedical Inc. earned $789.0K in net income for the twelve months ended Jun 30, 2026, a net margin of 2254.3%.How much cash and debt does IBO have?
Impact BioMedical Inc. reported $10.0K in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does IBO stock trade?
Impact BioMedical Inc. (IBO) is listed on AMEX.What sector and industry is IBO in?
Impact BioMedical Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Impact BioMedical Inc. go public?
Impact BioMedical Inc. (IBO) completed its IPO in 2024.What companies are similar to IBO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IBO side-by-side with any of them on Quantisnow.How can I track IBO on Quantisnow?
Quantisnow aggregates Impact BioMedical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IBO to receive live email and push alerts on every new disclosure.